Chronic Infection with Hepatitis C Virus Subtype 1g in a Japanese Patient Successfully Treated with Glecaprevir/Pibrentasvir.
Aged
Aminoisobutyric Acids
Antiviral Agents
/ therapeutic use
Benzimidazoles
Cyclopropanes
Drug Combinations
Genotype
Hepacivirus
/ genetics
Hepatitis C, Chronic
/ drug therapy
Humans
Japan
Lactams, Macrocyclic
Leucine
/ analogs & derivatives
Male
Persistent Infection
Phylogeny
Proline
/ analogs & derivatives
Pyrrolidines
/ therapeutic use
Quinoxalines
/ therapeutic use
Sulfonamides
glecaprevir/pibrentasvir
hepatitis C virus
subtype 1g
Journal
Internal medicine (Tokyo, Japan)
ISSN: 1349-7235
Titre abrégé: Intern Med
Pays: Japan
ID NLM: 9204241
Informations de publication
Date de publication:
15 May 2022
15 May 2022
Historique:
pubmed:
14
12
2021
medline:
18
5
2022
entrez:
13
12
2021
Statut:
ppublish
Résumé
A 66-year-old man, who had undergone plasma exchange 30 years previously in Egypt for the treatment of falciparum malaria, was referred to our hospital for treatment of chronic hepatitis C (HCV). An analysis of the 655-nucleotide 5'-untranslated region-core region sequence revealed infection with HCV subtype 1g. A phylogenetic analysis of the full-length HCV genome confirmed that the patient's HCV was subtype 1g, which was the first case identified in Japan. Although his HCV possessed several naturally occurring resistance-associated substitutions in the nonstructural (NS) 3 and NS5A regions, he was successfully treated by combination therapy with glecaprevir/pibrentasvir.
Identifiants
pubmed: 34897154
doi: 10.2169/internalmedicine.8673-21
pmc: PMC9177357
doi:
Substances chimiques
Aminoisobutyric Acids
0
Antiviral Agents
0
Benzimidazoles
0
Cyclopropanes
0
Drug Combinations
0
Lactams, Macrocyclic
0
Pyrrolidines
0
Quinoxalines
0
Sulfonamides
0
pibrentasvir
2WU922TK3L
Proline
9DLQ4CIU6V
Leucine
GMW67QNF9C
glecaprevir
K6BUU8J72P
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1537-1543Références
Sci Rep. 2018 Jan 26;8(1):1661
pubmed: 29374178
J Hepatol. 2017 Aug;67(2):224-236
pubmed: 28343981
J Viral Hepat. 2018 Nov;25(11):1287-1297
pubmed: 29888827
Arch Virol. 2011 Sep;156(9):1591-601
pubmed: 21643787
Epidemiol Infect. 2019 Jan;147:e234
pubmed: 31364570
J Hepatol. 2020 Nov;73(5):1170-1218
pubmed: 32956768
Arab J Gastroenterol. 2014 Jun;15(2):45-52
pubmed: 25097045
Hepatol Int. 2015 Oct;9(4):486-507
pubmed: 25941137
J Hepatol. 2017 Aug;67(2):263-271
pubmed: 28412293
J Gastroenterol Hepatol. 2020 May;35(5):855-861
pubmed: 31609495
Lancet. 2016 Sep 10;388(10049):1081-1088
pubmed: 27394647
World J Gastroenterol. 2021 Jul 14;27(26):4018-4044
pubmed: 34326611
Infect Drug Resist. 2019 Sep 19;12:2987-3015
pubmed: 31571951
J Hepatol. 2019 Dec;71(6):1099-1105
pubmed: 31400349
J Med Virol. 2018 Feb;90(2):304-312
pubmed: 28710853
Lancet Gastroenterol Hepatol. 2017 Mar;2(3):161-176
pubmed: 28404132
Drug Resist Updat. 2018 Mar;37:17-39
pubmed: 29525636
PLoS One. 2009 Dec 08;4(12):e8209
pubmed: 19997618
Lancet. 2015 Mar 21;385(9973):1075-86
pubmed: 25467591
J Infect Dis. 2021 Mar 01;:
pubmed: 33668068
J Viral Hepat. 2018 Nov;25(11):1270-1279
pubmed: 29851265
N Engl J Med. 2014 May 15;370(20):1889-98
pubmed: 24725239
Mol Biol Evol. 2016 Jul;33(7):1870-4
pubmed: 27004904
Lancet Gastroenterol Hepatol. 2019 Feb;4(2):119-126
pubmed: 30552056
Virology. 1993 Feb;192(2):430-7
pubmed: 7678473